Cat. #156404
USP9x-deficient DLD-1 (with or without p53) cell line
Cat. #: 156404
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Tissue: Colon
Disease: Cancer
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Fred Bunz
Institute: Johns Hopkins University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: USP9x-deficient DLD-1 (with or without p53) cell line
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: DLD-1
- Tissue: Colon
- Disease: Cancer
- Model: Knock-Out
- Description: This cell line presents an opportunity to study the effect of loss of apoptotic control on colorectal cancer cells. Study of deubiquitinase Ups9X could act as a leap towards understanding apoptotic regulation and potentially lead to new drug targets for cancer.In this technology, the gene USP9X is knocked out of two colorectal DLD-1 cells. The gene knockout has been performed by rAAV-mediated homologous recombination. The technology also consists of a double knockout line without USP9X and p53, a tumor suppressor gene.
Target Details
- Target: USP9X and p53
Handling
- Format: Frozen
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Harris et al. 2012. Cancer Biol Ther. 13(13):1319-24. PMID: 22895071.
